Allarity Therapeutics Inc (ALLR) Actualités

Form 8-K - Current report

Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer

Boston (February 6, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2...

Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC

Boston (January 30, 2025)—Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2...

Form 8-K - Current report

Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements

Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights

  Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib...

Form 8-K - Current report